NASDAQ:ADTX Aditxt (ADTX) Stock Price, News & Analysis $1.51 -0.03 (-1.95%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$1.50 -0.01 (-0.99%) As of 06/9/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aditxt Stock (NASDAQ:ADTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aditxt alerts:Sign Up Key Stats Today's Range$1.46▼$1.5550-Day Range$1.36▼$5.5852-Week Range$1.34▼$27,200.00Volume75,548 shsAverage Volume794,757 shsMarket Capitalization$3.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Read More… Aditxt Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreADTX MarketRank™: Aditxt scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Aditxt. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioAditxt has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aditxt's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.14% of the float of Aditxt has been sold short.Short Interest Ratio / Days to CoverAditxt has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aditxt has recently increased by 0.89%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAditxt does not currently pay a dividend.Dividend GrowthAditxt does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.14% of the float of Aditxt has been sold short.Short Interest Ratio / Days to CoverAditxt has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aditxt has recently increased by 0.89%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.25 News SentimentAditxt has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aditxt this week, compared to 1 article on an average week.Search Interest4 people have searched for ADTX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aditxt to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aditxt insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Aditxt is held by insiders.Percentage Held by InstitutionsOnly 15.54% of the stock of Aditxt is held by institutions.Read more about Aditxt's insider trading history. Receive ADTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aditxt and its competitors with MarketBeat's FREE daily newsletter. Email Address ADTX Stock News HeadlinesEvofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of DirectorsJune 9 at 8:42 AM | finance.yahoo.comEvofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of DirectorsJune 9 at 8:15 AM | businesswire.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.June 10, 2025 | Brownstone Research (Ad)Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6June 5, 2025 | businesswire.comAditxt (NASDAQ:ADTX) Shares Down 8.1% - Time to Sell?June 3, 2025 | americanbankingnews.comAditxt Highlights Strategic Partnership with Evofem BiosciencesJune 2, 2025 | tipranks.comAditxt Announces Termination of Arrangement Agreement With Appili TherapeuticsMay 19, 2025 | finance.yahoo.comAditxt Discusses Strategic Focus and Growth PlansMay 19, 2025 | tipranks.comSee More Headlines ADTX Stock Analysis - Frequently Asked Questions How have ADTX shares performed this year? Aditxt's stock was trading at $47.45 at the beginning of 2025. Since then, ADTX shares have decreased by 96.8% and is now trading at $1.51. View the best growth stocks for 2025 here. How were Aditxt's earnings last quarter? Aditxt, Inc. (NASDAQ:ADTX) released its earnings results on Thursday, May, 15th. The company reported ($8.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($26,400.00) by $26,391.88. The firm had revenue of $0 million for the quarter, compared to analyst estimates of $0.43 million. When did Aditxt's stock split? Aditxt shares reverse split before market open on Monday, March 17th 2025. The 1-250 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 14th 2025. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. Who are Aditxt's major shareholders? Aditxt's top institutional investors include IFP Advisors Inc (17.64%). Insiders that own company stock include Paribas Securities Corp Bnp, Financial Lp Hrt and Amro A Albanna. View institutional ownership trends. How do I buy shares of Aditxt? Shares of ADTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aditxt own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aditxt investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Plug Power (PLUG), SNDL (SNDL), AMC Entertainment (AMC) and Walt Disney (DIS). Company Calendar Last Earnings5/15/2025Today6/09/2025Next Earnings (Estimated)8/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADTX CIK1726711 Webwww.aditxt.com Phone650-870-1200FaxN/AEmployees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$32.38 million Net MarginsN/A Pretax Margin-30,525.09% Return on Equity-439.07% Return on Assets-122.96% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.08 Sales & Book Value Annual Sales$55.32 thousand Price / Sales57.86 Cash FlowN/A Price / Cash FlowN/A Book Value$2,687.49 per share Price / Book0.00Miscellaneous Outstanding Shares2,120,000Free Float14,233,000Market Cap$3.20 million OptionableNo Data Beta1.49 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ADTX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWall Street Legend: Crash coming in March—details hereBad News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history give...Chaikin Analytics | SponsoredTrump’s treachery A few months ago, I released a list of six companies I believed were going to appreciate under Trump’s second ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s “Secret Mission”Tesla, SpaceX and Starlink made billions for investors... But a meeting Elon had on March 21st, 2025, could...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aditxt, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aditxt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.